Jiri Kryza

ABSTRACT Prostate cancer is a significant health concern in the Czech Republic, with a high incidence rate among men. This study assesses the current practices and management strategies of Czech oncologists in treating metastatic prostate cancer. A survey of 27 oncologists revealed that 42.2% of patients were currently with metastatic castration-resistant prostate cancer (mCRPC), followed by 27.6% with non-metastatic hormone-sensitive prostate cancer (nmHSPC), 22.7% with metastatic hormone-sensitive prostate cancer (mHSPC), and 7.4% with non-metastatic castration-resistant prostate cancer (nmCRPC). The majority of referrals (74.1%) came from urologists. Specific treatment choices for mCRPC patients included abiraterone (40.7%) and enzalutamide (29.6%). The findings highlight the need for early detection and intervention strategies to improve patient outcomes and support the design of future clinical trials.